Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • Malaria, vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D and Introduction
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
        • The decision-making framework for malaria vaccines
        • Economic analysis
        • Public health impact analysis
        • Sociocultural research
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Malaria, vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D and Introduction
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Home
  • Home

PATH applauds WHO recommendation for broader use of first malaria vaccine in sub-Saharan Africa

Vaccine shown to be cost-effective and trusted by caregivers and health care workers

PATH welcomes landmark financing agreement for GSK's malaria vaccine

PATH congratulates Gavi, GSK, and MedAccess for joining forces to help ensure an ongoing supply of the first malaria vaccine, RTS,S/AS01E. 

PATH welcomes WHO prequalification of the first malaria vaccine

The vaccine's prequalification is a key step in protecting children and reducing the burden of malaria.

PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S

Together with partners and other stakeholders, PATH is working to help ensure sufficient malaria vaccine supply to meet potential demand.

Home

  • Malaria parasite life cycle

    Many factors make malaria vaccine development challenging.
    Explore
  • R&D and Introduction

    MVI's strategy supports the near-term goal of controlling malaria in the populations most at risk, as well as the long-term goal of complete eradication of the disease.
    Explore
  • RTS,S

    RTS,S is the first malaria vaccine recommended for broad use by WHO
    Explore

Latest

PATH welcomes WHO prequalification of the first malaria vaccine
Press release
6 Sep 2022
RTS,S/AS01 malaria vaccine being drawn up by a healthcare worker in western Kenya. PATH welcomes US$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi
Press release
19 Apr 2022
PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S
Press release
2 Dec 2021
PATH applauds WHO recommendation for broader use of first malaria vaccine
Press release
6 Oct 2021
PATH welcomes remarkable results from clinical trial combining RTS,S/AS01 malaria vaccine with Seasonal Malaria Chemoprevention
Press release
25 Aug 2021
Frequently Asked Questions (FAQs): RTS,S/AS01 for seasonal use
Fact sheet
25 Aug 2021
PATH welcomes landmark financing agreement for GSK’s malaria vaccine
Press release
4 Aug 2021
Frequently Asked Questions (FAQs): Product Transfer for the RTS,S/AS01 Malaria Vaccine
Fact sheet
27 Jan 2021
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
Press release
27 Jan 2021
Milestone study identifies immune markers that may help predict success of vaccination with RTS,S/AS01 malaria vaccine
Press release
22 Jul 2020
PATH receives new five-year contract from USAID for malaria vaccine research and development
Press release
7 Jul 2020
A child sits with his mother Two families reflect on their malaria vaccine journey
Feature
23 Apr 2020
  • Need for vaccines

    Vaccines can help to close the gap left by other malaria control interventions.
  • Malaria vaccine roadmap

    The roadmap outlines a path for accelerating the development of malaria vaccines.
  • RTS,S

    RTS,S is the first malaria vaccine recommended for broad use by WHO
  • Next-generation vaccines

    The next generation of malaria vaccines would aim to increase efficacy, durability or protection...

Twitter @MalariaVaccine

RT @WHO: @DrTedros @GlobalGoalsUN @UN @UNEP "Meanwhile, the 🌍’s first #malaria vaccine, RTS,S, is saving lives. In 🇬🇭, 🇰🇪 &… https://t.co/A8Q8drysX6
30 Jan 2023
RT @Fredros_Inc: What if the RTS,S Malaria vaccine is seasonally-targeted? ~ Thompson et al: Seasonally targeting RTS,S may yield gr… https://t.co/jLXpHIKDmW
27 Jan 2023
RT @dsw_intl: We’re looking forward to hearing from @PeterHotez and @PCuresResearch at the launch of the upcoming #GFINDER… https://t.co/GM6uw38ioC
26 Jan 2023
RT @BranwenHennig: The OPT-SMC team under Jean-Louis Ndiaye in Sengal and partners incl @ADP_health @TDRnews @PATHtweets put together… https://t.co/jHhQAfIuSc
23 Jan 2023
RT @E8_Malaria: Excitement builds in Malawi for malaria vaccine launch https://t.co/0eQJp7t5gD via @gavi
17 Jan 2023
RT @MalariaPapers: The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule… https://t.co/y5QObXScKh
10 Jan 2023
RT @PATHMalaria: #HappyNewYear!🎉 On behalf of the entire PATH Malaria team, we wish you all a great start to 2023. We look forward… https://t.co/jDGqB3e85T
5 Jan 2023
RT @PATHMalaria: #PATHMalaria2022: In July, RTS,S/AS01 (RTS,S) became the first malaria vaccine to be prequalified by @WHO. This des… https://t.co/G5kfXHqk68
21 Dec 2022
RT @NanthalileM: In July this year, #malariavaccine was prequalified by @WHO, & together with the global malaria community, we have… https://t.co/yhbVMgjAXC
19 Dec 2022
RT @WHOMalawi: The RTS,S malaria vaccine is the 1st vaccine recommended for use to prevent malaria & significantly reduces life-th… https://t.co/mGv1OONXTL
13 Dec 2022
RT @DavidReddy_MMV: R&D is crucial for developing tools to #endmalaria. Several product development partnerships, including… https://t.co/igwA7VfpXl
12 Dec 2022
RT @theglobalfight: Read highlights from @WHO's World #Malaria Report ➡️76% of all #malaria deaths in 2021 were children under the age… https://t.co/HW3WJMAhTF
9 Dec 2022

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2023 PATH
Website by Manta Ray Media